June 30, 2010
Baeta Corp. Registration Statement Approved by the United States Securities and Exchange Commission
Common Stock of Baeta Corp. to trade under the symbol BAEA.OB
Baeta Corp. is pleased to announce it has completed a Registration Statement with the United States Securities and Exchange Commission effective May 14, 2010.
Under the Registration Statement, investors will in the near future be able to buy and sell shares of Baeta Corp. common stock via the OTC Bulletin Board (OTCBB) using the stock symbol, BAEA.OB.
“As we continue to expand the offerings of Baeta Corp, we are delighted to enable additional investors to partake in the participatory healthcare model—empowering patients to actively elevate their role in the prevention, diagnosis, treatment, and recovery from illnesses,” said Dr. Alexander Gak, Baeta Corp. Chairman and President.
“Our revolutionary MyHealthTrends product suite was designed by a physician to be patient-friendly, uniquely capture and report high fidelity data, and address patient ailments across many large and growing sectors—starting with weight control and pain management,” said Len Pushkantser, Chief Executive Officer of Baeta Corp.
This announcement is neither an offer to sell nor a solicitation of an offer to buy any shares of common stock, warrants or other securities of Baeta Corp. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
More Information
For additional information please contact:
Len Pushkantser
Chief Executive Officer
201.471.0988 X106
ir@baetacorp.com
About Baeta Corp.
Baeta Corp. is a technology-enabled health improvement company empowering patients to elevate their role in the prevention, diagnosis, treatment, and recovery from illnesses. Baeta Corp. develops innovative, technology-driven healthcare information solutions enabling patients to easily capture health-related data. Please visit us at http://www.baetacorp.com/
Safe Harbor & Disclaimer
Statements pertaining to a company's future value and growth potential are considered "forward-looking" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. Baeta Corp. intends that such statements and all forward-looking statements be subject to the safe harbors created thereby. Actual results may differ significantly from those expressed or implied. Information has been carefully compiled from sources deemed to be reliable, but accuracy is not guaranteed. Investing in securities is speculative and carries a high degree of risk. All information should be independently verified. Investors need to perform their own due diligence with any investment decision to fully understand all risks. This release has been prepared by Baeta Corp. and should not be constituted in any way as an offer to sell or acquire any securities. For additional information, please contact Baeta Corp. at 201.471.0988.
MyHealthTrends combines handheld device technology, computer software, and the Internet to easily allow patients to record their food cravings whenever and wherever they occur. A small, handheld portable device allows patients to record their cravings and responses as directed by their healthcare professional.
"Our objective is to easily empower patients to monitor their own cravings, create a level of self awareness and accountability, and facilitate behavior modification at the direction of healthcare professionals," said Leonid Pushkantser, CEO of Baeta Corp. "MyHealthTrends is among the industry's first steps in this important direction," said Pushkantser.
MyHealthTrends for Weight Control is a vital tool for patients and healthcare professionals providing:
"MyHealthTrends for Weight Control is the first in a series of technology-driven healthcare solutions empowering patients and healthcare professionals to measure and improve treatment," said Dr. Alexander Gak, Founder and Chairman of Baeta Corp. "We are excited to usher in a new era of truly participatory healthcare," said Gak.
September 21, 2009
Baeta Corp. Presents Abstract of MyHealthTrends for Pain at PAINWeek 2009 Conference
MyHealthTrends for Pain ushers in a new era of portable, patient-centric pain recording devices.
Las Vegas, NV, September 11, 2009 — The findings of a study reviewing the efficacy of MyHealthTrends for Pain as a quantitative pain monitoring solution were presented at the PAINWeek 2009 Conference by Dr. Michael Semenovski and Dr. Marco Pappagallo.
The study entitled "Miniature Electronic Diary Device for Patient Based Registration of Pain Sensation at Minute Intervals with Internet Communicability" consisted of multiple patients, each with chronic pain. The research reveals the simplicity of the portable, handheld MyHealthTrends device improves pain recording compliance compared to traditional recall-based paper diary approaches and more elaborate screen-based electronic diary systems.
"We are delighted to share the findings conducted by an esteemed team of professionals including: Dr. Alex Bekker, Dr. Marco Pappagallo, Dr. Samyadev Datta, and Dr. Lauren Shaiova, Dr. Richard Kline, Dr. Michael Semenovski, and Dr. Leonid Topper," said Len Pushkantser, CEO of Baeta Corp. "We are particularly excited about the opportunity to dramatically improve the accuracy and ease of pain reporting using MyHealthTrends’ patient-centric, user friendly device—which we believe will directly lead to improved patient treatment and care," said Mr. Pushkantser.
To view images and a brief video from the PAINWeek 2009 Conference, please visit: http://www.baetacorp.com/news_PAINWeek_2009.aspx
About Baeta Corp.
Baeta Corp. is a technology-enabled health improvement company empowering patients to elevate their role in the prevention, diagnosis, treatment, and recovery from illnesses. Baeta Corp. develops innovative, technology-driven healthcare information solutions enabling patients to easily capture health-related data.
More Information:
Len Pushkantser, Chief Executive Officer
201.471.0988
info@baetacorp.com
Safe Harbor & Disclaimer:
Statements pertaining to a company's future value and growth potential are considered "forward-looking" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. Baeta Corp. intends that such statements and all forward-looking statements be subject to the safe harbors created thereby. Actual results may differ significantly from those expressed or implied. Information has been carefully compiled from sources deemed to be reliable, but accuracy is not guaranteed. Investing in securities is speculative and carries a high degree of risk. All information should be independently verified. Investors need to perform their own due diligence with any investment decision to fully understand all risks. This release has been prepared by Baeta Corp. and should not be constituted in any way as an offer to sell or acquire any securities. For additional information, please contact Baeta Corp. at 201.471.0988.
July 14, 2009
BAETA Corp. Announces Formation of Management Team
BAETA Corp. announced today the formation of its management team responsible for the daily operation of the company.
"I am personally and professionally delighted to welcome such a team of seasoned and uniquely qualified individuals to BAETA Corp," said Dr. Alexander Gak, BAETA Corp. Chairman. "Each member of the management team brings exceptional skills and expertise across a multitude of functional areas. Working together, I look forward to rapidly accelerating the growth of BAETA Corp." said Gak.
Members of the management team include:
- Len Pushkantser, Chief Executive Officer
- Jeff Burkland, Chief Financial Officer
- Eugene Gribov, Chief Technology Officer
- Lee Smith, Chief Marketing Officer
- Leonid Topper, M.D., Chief Medical Officer
Len Pushkantser, Chief Executive Officer
Working in the manufacturing and medical industries for more than two decades, Mr. Pushkantser has proven experience manufacturing and bringing new products to market -- both domestically and internationally. Mr. Pushkantser's skills and experiences have been an essential ingredient in driving continuous growth.
Prior to joining Baeta Corp., Mr. Pushkantser was the Vice President of Operations for AFC Industries where he was responsible for engineering, manufacturing, quality assurance, customer service, human resources, cost accounting and profitability, and compliance with FDA, EPA, and OSHA standards. Previously, Mr. Pushkantser was also a Director of Manufacturing, Plant Manager and Processing Manager for an FDA regulated automated cancer screening test.
Mr. Pushkantser received a Master's of Science in Business Operations and a Bachelor's of Science in Mechanical Engineering -- both from Polytechnic University in Kiev, Ukraine.
Jeff Burkland, Chief Financial Officer
Mr. Burkland has over 15 years of strategic and tactical financial management experience. Adept in business plan development, process improvement, SOX compliance, and pre-public company financing, Mr. Burkland has shaped and managed the financial function for numerous companies including those in the technology and manufacturing industries.
Previously Mr. Burkland was the Vice President of Finance and Operations for Synaptex, a software company focused upon information management. As a member of the senior management team, Mr. Burkland developed the business plan and forecasts for the company. Mr. Burkland also worked for UTStarcom, Zhone Technologies, NorthPoint Communications, and AT&T where he developed and implemented plans to penetrate new markets, capture market share, and increase margins.
Mr. Burkland received an MBA from the Harvard Business School and a Bachelor's of Science in Electrical Engineering and Economics from Duke University -- Summa Cum Laude.
Eugene Gribov, Chief Technology Officer
Mr. Gribov has more than 20 years of international engineering management, product development, and offshore manufacturing management experience across a wide array of sectors including the Information Technology and Medical industries.
Mr. Gribov is the President of Globe Audio Design Inc. which develops high-power audio solutions. Previously Mr. Gribov designed semiconductor, integrated circuitry, optoelectronic, and software-based solutions for Kintek Inc. and Globe Ltd. Further showcasing Mr. Gribov's technical skills, he worked in a select group of researchers under the direct supervision of Nobel Prize winner, Zhores Alferov.
Mr. Gribov graduated with honors from Sankt-Peterburgskij Gosudarstvennyj Elektrotehniceskij Universitet (LETI) with a Master's of Science in Electrical Engineering.
Lee Smith, Chief Marketing Officer
With more than 20 years of experience in the technology, marketing, and advertising industries, Mr. Smith has a demonstrated track record of developing new products, defining successful brands, creating marketplace awareness, and driving sales.
Mr. Smith is the President and CEO of Persuasive Brands, a marketing services agency dedicated to branding and sales generation. Previously, Mr. Smith was the founder, COO, and acting CEO of InsightExpress, a firm he grew to one of the 50 largest market research companies in the United States in six years. Mr. Smith's innovative ideas and business practices have been recognized via four U.S. patents.
Mr. Smith holds an MBA in Marketing and Finance from Carnegie Mellon University's Tepper Business School and a Bachelor's of Science in Computer Science from The Pennsylvania State University.
Leonid Topper, M.D., Chief Medical Officer
Dr. Topper is a Board Certified Neurologist with a specialty in Pediatric Neurology. Currently an Attending Neurologist with Pediatric Neurology Associates, Dr. Topper has extensive experience in the diagnosis and management of patients with seizures, epilepsy, headaches, brain infections, stroke, tics and Tourette syndrome, nerve and muscle conditions, autistic disorders, ADHD, and neonatal brain problems.
Previously, Dr. Topper was an Attending Pediatric Neurologist at Schneider Children's Hospital and an Attending Pediatric Neurologist at Chaim Sheba Medical Center in Israel.
An internationally distinguished lecturer and prolific author, Dr. Topper is an Examiner for The American Board of Psychiatry and Neurology. Dr. Topper is also a member of The Royal College of Pediatrics and Child Health in the United Kingdom.
Dr. Topper received his Doctor of Medicine Degree from Kaunas Medical Academy in Kaunas, Lithuania conducted his internship at Vilnius Children's Hospital in Vilnius, Lithuania.
To view this information online with accompanying photographs, please visit: http://www.baetacorp.com/COMPANY_Management.aspx
About BAETA Corp.
BAETA Corp. is a technology-enabled health improvement company empowering patients to elevate their role in the prevention, diagnosis, treatment, and recovery from illnesses. BAETA Corp. develops innovative, technology-driven healthcare information solutions enabling patients to easily capture health-related data.
More Information:
Dr. Alexander Gak, Chairman
Len Pushkantser, Chief Executive Officer
201.849.4555
info@baetacorp.com
Safe Harbor & Disclaimer:
Statements pertaining to a company's future value and growth potential are considered "forward-looking" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. BAETA Corp. intends that such statements and all forward-looking statements be subject to the safe harbors created thereby. Actual results may differ significantly from those expressed or implied. Information has been carefully compiled from sources deemed to be reliable, but accuracy is not guaranteed. Investing in securities is speculative and carries a high degree of risk. All information should be independently verified. Investors need to perform their own due diligence with any investment decision to fully understand all risks. This release has been prepared by BAETA Corp. and should not be constituted in any way as an offer to sell or acquire any securities. For additional information, please contact BAETA Corp. at 201.849.4555.
February 9, 2009
BAETA Corp. Announces the Formation of Scientific Advisory Board
Members are renowned, world-class doctors specializing in pain management
BAETA Corp. announced today the formation of its Scientific Advisory Board to oversee in-hospital usage of BAETA offerings and to help shape the company’s future product portfolio.
"We are delighted to have an Advisory Board composed of such esteemed and accomplished medical professionals," said Dr. Alexander Gak, BAETA Corp. Chairman and CEO. "Each member brings decades of experience advancing the understanding and treatment of pain—fundamentally improving the lives of patients. We look forward to the contributions and expertise of these uniquely qualified healthcare innovators and practitioners." said Gak.
The members of the BAETA Corp. Scientific Advisory Board include:
Alex Y. Bekker, M. D., Ph. D.
Professor of Anesthesiology and Neurosurgery and Vice Chair for Research at NYU School of Medicine in New York; Attending Anesthesiologist, New York University Medical Center and Bellevue Hospital in New York. Dr. Bekker is Chairman of the Scientific Advisory Board for BAETA Corp.
Dr. Bekker earned his Ph.D. in Biomedical Engineering from the New Jersey Institute of Technology in Newark and his M.D. from University of Medicine and Dentistry of New Jersey. Completing his residency in anesthesiology at Columbia-Presbyterian Medical Center in New York, Dr. Bekker has a longstanding interest in the perioperative management of geriatric patients. Dr. Bekker has served as the principal investigator of numerous clinical trials related to perioperative care of the elderly, treatment of acute pain and postoperative nausea and vomiting, and clinical pharmacology of new analgesics and sedatives. The author of more than 50 original papers in peer-reviewed journals, Dr. Bekker is regularly invited to present lectures and moderate scientific panels at the most prestigious national and international anesthesiology/pain management meetings. Dr. Bekker is internationally recognized as an expert in clinical pharmacology, neuroanesthesia, postoperative pain management and perioperative organ protection.
Click to view the detailed resume of Dr. Bekker.
Marco Pappagallo, M.D.
Professor, Department of Anesthesiology and Director of Pain Medicine Research and Development at the Mount Sinai School of Medicine in New York, New York.
Dr. Pappagallo is one of the foremost experts in the field of pain medicine. Since mid-2006, Dr. Pappagallo has served as a Professor in the Department of Anesthesiology at Mount Sinai School of Medicine in New York City, where he is also an Director of Pain Medicine Research and Development and Attending Physician.
In the past, Dr. Pappagallo held the titles of Director-Division of Chronic Pain and Attending Physician in the Department of Pain Medicine and Palliative Care at Beth Israel Medical Center in New York City, and prior to this, Director of the Comprehensive Pain Treatment Center and Attending Physician in the Department of Neurology at the Hospital for Joint Diseases, in New York City. He also served as an Attending Physician in the Department of Neurology and Director, Division of Pain Medicine (Department of Neurology) at The Johns Hopkins Medical Institutions in Baltimore. Dr Pappagallo has also served as an Associate Professor in the departments of Neurology and Anesthesiology at Albert Einstein College of Medicine and the NYU School of Medicine, both in New York.
Click to view the detailed resume of Dr. Pappagallo.
Samyadev Datta, M.B., B.S., FRCA.
Director, Center for Pain Management in Hackensack, New Jersey.
Dr. Datta earned his medical degree from the Government Medical College in Mysore, India. Board Certified in anesthesiology from three countries, Dr. Datta conducted his most recent postdoctoral training in anesthesiology and pain management at Columbia Presbyterian Medical Center, Memorial Sloan-Kettering Cancer Center, and Cornell University Medical College, all in New York, New York.
An author of numerous articles, contributor to multiple books, and frequent guest speaker, Dr. Datta is a member of the Association of Anaesthetists of Great Britain and Ireland, American Society of Anesthesiology, International Association for the Study of Pain, International Spinal Intervention Society, and American Society of Interventional Pain Physicians. As a nationally recognized expert in pain management, Dr. Datta has served on the Advisory Boards of Faulding Laboratories and Janssen Pharmaceuticals, among others. He is presently involved in multiple drug trials.
Click to view the detailed resume of Dr. Datta.
About BAETA Corp.
BAETA Corp. develops and manufactures consumer medical products intended to address Chronic Pain Management and Vital Signs Monitoring markets. BAETA Corp's first product, MyPainAway, is currently being manufactured and available for sale to consumers.
More Information:
Dr. Alexander Gak, President & CEO
Douglas A Rogers, Interim CFO
(201) 471-0998
info@baetacorp.com
Safe Harbor & Disclaimer:
Statements pertaining to a company's future value and growth potential are considered "forward-looking" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. BAETA Corp. intends that such statements and all forward-looking statements be subject to the safe harbors created thereby. Actual results may differ significantly from those expressed or implied. Information has been carefully compiled from sources deemed to be reliable, but accuracy is not guaranteed. Investing in securities is speculative and carries a high degree of risk. All information should be independently verified. Investors need to perform their own due diligence with any investment decision to fully understand all risks. This release has been prepared by BAETA Corp. and should not be constituted in any way as an offer to sell or acquire any securities. For additional information, please contact BAETA Corp. at (210) 471-0998.
January 12, 2009
BAETA Corp. Accepts Invitation to Integrate Its Online Products within the Be-Alive Portal
MyPainAway is the first of the BAETA Corp. products available via www.Be-Alive.org
BAETA Corp., an innovative provider of technology-driven healthcare information solutions enabling patients to easily capture vital data to help medical professionals measure and improve treatment, announces it has been invited by Extranome, Inc. to include its online products within the www.Be-Alive.org Portal.
"We are delighted to join www.Be-Alive.org to provide easy, seamless access to MyPainAway for all of our current and future customers," said Dr. Alexander Gak, Chairman and CEO of BAETA Corp. "We view the BeAlive Portal as the next generation vehicle enabling consumers, patients, and medical professionals to obtain integrated access to both public and personal information. We look forward to making MyHealthID and future BAETA Corp. offerings available via the BeAlive Portal," said Gak.
The BeAlive Portal, www.Be-Alive.org, is an integrated, secure online solution providing easy access to personal online products, public Internet content, and email. BeAlive helps individual consumers easily acquire the information of interest to them while helping online enterprises experience heightened activity levels and revenue.
About BAETA Corp.
BAETA Corp. develops and manufactures consumer medical products intended to address Chronic Pain Management and Vital Signs Monitoring markets. BAETA Corp's first product, MyPainAway, is currently being manufactured and available for sale to consumers.
More Information:
Dr. Alexander Gak, President & CEO
Douglas A Rogers, Interim CFO
(201) 471-0998
info@baetacorp.com
Safe Harbor & Disclaimer:
Statements pertaining to a company's future value and growth potential are considered "forward-looking" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. BAETA Corp. intends that such statements and all forward-looking statements be subject to the safe harbors created thereby. Actual results may differ significantly from those expressed or implied. Information has been carefully compiled from sources deemed to be reliable, but accuracy is not guaranteed. Investing in securities is speculative and carries a high degree of risk. All information should be independently verified. Investors need to perform their own due diligence with any investment decision to fully understand all risks. This releease has been prepared by BAETA Corp. and should not be constituted in any way as an offer to sell or acquire any securities. For additional information, please contact BAETA Corp. at (210) 471-0998.
December 29, 2008
BAETA Corp. Announces the Availability of MyPainAway
MyPainAway ushers in a new era empowering individuals to record and help contribute to the pain management process
BAETA Corp. announces today the availability of MyPainAway, a pioneering pain recording and reporting solution for those afflicted with pain.
Developed by a medical doctor to help those afflicted by pain associated with Fibromyalgia, Arthritis, Cancer Lupus, Migraines and headaches, Depression, Sciatica, Herniated Discs, injuries, or other sources, MyPainAway easily enables individuals to record their sensations - helping them to work in concert with their medical professionals to acquire faster and superior diagnoses and treatment.
"We are delighted to usher in a new era empowering individuals to record and actively participate in the management and treatment of chronic and acute pain," said Dr. Alexander Gak, Chairman and CEO of BAETA Corp. "The World Health Organization (WHO) states the ability to live without pain is now a fundamental, inalienable human right and we believe MyPainAway is a landmark solution providing unparalleled benefits for patients and medical practitioners directly in line with the WHO's position on pain," said Gak.
MyPainAway combines the latest hand-held device, computer software, and Internet technology empowering individuals to record their pain whenever and wherever it occurs. Using a computer or access to the Internet, patients can view and share graphical representations of their pain - indicating frequency, intensity, and other metrics over time.
To learn more about MyPainAway, please visit our product website, www.mypainaway.com. MyPainAway is also available for purchase.
About BAETA Corp.
BAETA Corp. develops and manufactures consumer medical products intended to address Chronic Pain Management and Vital Signs Monitoring markets. BAETA Corp's first product, MyPainAway, is currently being manufactured and expected to be available for sale to consumers during the fourth quarter of 2008.
More Information:
Dr. Alexander Gak, President & CEO
Douglas A Rogers, Interim CFO
(201) 471-0998
info@baetacorp.com
Safe Harbor & Disclaimer:
Statements pertaining to a company's future value and growth potential are considered "forward-looking" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. BAETA Corp. intends that such statements and all forward-looking statements be subject to the safe harbors created thereby. Actual results may differ significantly from those expressed or implied. Information has been carefully compiled from sources deemed to be reliable, but accuracy is not guaranteed. Investing in securities is speculative and carries a high degree of risk. All information should be independently verified. Investors need to perform their own due diligence with any investment decision to fully understand all risks. This releease has been prepared by BAETA Corp. and should not be constituted in any way as an offer to sell or acquire any securities. For additional information, please contact BAETA Corp. at (210) 471-0998.
October 14, 2008
BAETA Corp. Files S-1 with the Securities and Exchange Commission
BAETA Corp. offers 946,680 common shares via the secondary, public market
BAETA Corp. announced today that it has filed its Prospectus Statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") to sell approximately 946,680 common shares in the secondary, or public market. BAETA Corp. is registering for re-sale, shares acquired privately by a number of individual shareholders in a recent private offering of common stock completed by BAETA Corp. BAETA Corp. is also registering a number of shares held by various service providers that have accepted equity-in-lieu payments for services rendered during BAETA Corp.'s commercial development.
Upon being deemed effective by the SEC, the shares registered will become available for re-sale in the public markets, by those individuals and corporations included in the registration statement. BAETA Corp. anticipates that, when it achieves this milestone, its shares will trade in the U.S. Over The Counter ("OTC") market.
For more information, or to view BAETA Corp.'s prospectus in its entirety, please see: http://www.sec.gov/Archives/edgar/data/1439636/000114420408057575/v128818_s1.htm
About BAETA Corp.
BAETA Corp. develops and manufactures consumer medical products intended to address Chronic Pain Management and Vital Signs Monitoring markets. BAETA Corp's first product, MyPainAway, is currently being manufactured and expected to be available for sale to consumers during the fourth quarter of 2008.
More Information:
Dr. Alexander Gak, President & CEO
Douglas A Rogers, Interim CFO
(201) 471-0998
info@baetacorp.com
Safe Harbor & Disclaimer:
Statements pertaining to a company's future value and growth potential are considered "forward-looking" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. BAETA Corp. intends that such statements and all forward-looking statements be subject to the safe harbors created thereby. Actual results may differ significantly from those expressed or implied. Information has been carefully compiled from sources deemed to be reliable, but accuracy is not guaranteed. Investing in securities is speculative and carries a high degree of risk. All information should be independently verified. Investors need to perform their own due diligence with any investment decision to fully understand all risks. This releease has been prepared by BAETA Corp. and should not be constituted in any way as an offer to sell or acquire any securities. For additional information, please contact BAETA Corp. at (210) 471-0998.
